A Change of Serum Prostate Specific Antigen Correlated with Clinical Status of Prostate Cancer Patient.
- Author:
Won Hee WOO
1
;
Sung Goo CHANG
Author Information
1. Department of Urology, School of Medicine, Kyung Hee University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Prostate cancer;
Prostate specific antigen
- MeSH:
Adenocarcinoma;
Diagnosis;
Humans;
Lymphatic Metastasis;
Magnetic Resonance Imaging;
Neoplasm Grading;
Neoplasm Metastasis;
Prostate*;
Prostate-Specific Antigen*;
Prostatectomy;
Prostatic Neoplasms*;
Recurrence;
Retrospective Studies;
Thorax;
Urology
- From:Korean Journal of Urology
1998;39(6):580-584
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: It has been reported that serum prostate specific antigen(PSA) generally increase in direct proportion to clinical status of prostate cancer, but some reports suggest that PSA level is not correlated with clinical stage in 10% of the patients of prostate cancer. We evaluate the value of PSA about clinical status of prostate cancer through comparing disease status and PSA of patient at initial diagnosis of prostate cancer. MATERIALS AND METHODS: A clinical study was retrospectively made on sixty patients with prostate adenocarcinoma. The patients were admitted to the Department of Urology between January of 1992 and December of 1996. Results were obtained through statistical analysis of the correlation between PSA level and clinical status by performing serum PSA, chest X-ray, bone scan, pelvic CT or pelvic MRI. At the time of the analysis patients were diagnosed with prostate adenocarcinoma pathologically. RESULTS: Mean PSA level of patients with bone metastasis and no metastasis was 125.4 and 97.89ng/m1, respectively and correlation between the two groups was not observed, so bone scan could not be replaced by measuring serum PSA. The number of hot uptake In bone scan wasn't correlated with serum PSA level. Gleason score wasn't correlated with serum PSA level. Multiple comparisons in groups which were classified by bone metastasis and lymphatic metastasis had no statistical significance. CONCLUSIONS: As the result of the above observations, we predict that there is a problem in evaluating clinical status with PSA as compared with the value at initial diagnosis or as a predictor of recurrence in patients with radical prostatectomy.
